AU2001280883A1 - Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis - Google Patents

Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Info

Publication number
AU2001280883A1
AU2001280883A1 AU2001280883A AU8088301A AU2001280883A1 AU 2001280883 A1 AU2001280883 A1 AU 2001280883A1 AU 2001280883 A AU2001280883 A AU 2001280883A AU 8088301 A AU8088301 A AU 8088301A AU 2001280883 A1 AU2001280883 A1 AU 2001280883A1
Authority
AU
Australia
Prior art keywords
vaccines
protection against
diseases caused
broad spectrum
neisseria meningitidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280883A
Inventor
Dan Granoff
Gregory R. Moe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Oakland Research Center
Original Assignee
CHILDREN S HOSPITAL OAKLAND RE
Childrens Hospital Oakland Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHILDREN S HOSPITAL OAKLAND RE, Childrens Hospital Oakland Research Institute filed Critical CHILDREN S HOSPITAL OAKLAND RE
Publication of AU2001280883A1 publication Critical patent/AU2001280883A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
AU2001280883A 2000-07-27 2001-07-27 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis Abandoned AU2001280883A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22149500P 2000-07-27 2000-07-27
US60221495 2000-07-27
PCT/US2001/023842 WO2002009643A2 (en) 2000-07-27 2001-07-27 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Publications (1)

Publication Number Publication Date
AU2001280883A1 true AU2001280883A1 (en) 2002-02-13

Family

ID=22828056

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280883A Abandoned AU2001280883A1 (en) 2000-07-27 2001-07-27 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Country Status (12)

Country Link
US (2) US6936261B2 (en)
EP (1) EP1322328B1 (en)
JP (1) JP5511117B2 (en)
KR (1) KR20030024811A (en)
AU (1) AU2001280883A1 (en)
BR (1) BRPI0112928B1 (en)
CA (1) CA2416137C (en)
CR (1) CR6880A (en)
EC (1) ECSP034447A (en)
ES (1) ES2519440T3 (en)
MX (1) MXPA03000822A (en)
WO (1) WO2002009643A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
NZ508771A (en) 1998-05-29 2003-08-29 Chiron Corp Neisseria meningitidis vaccine comprising NmC oligosaccharides, NmB outer membrane proteins, and a carrier
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP2270172B1 (en) 1999-05-19 2016-01-13 GlaxoSmithKline Biologicals SA Combination neisserial compositions
CN1796404A (en) 1999-10-29 2006-07-05 启龙有限公司 Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ATE378348T1 (en) 2000-01-14 2007-11-15 Us Health OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE
MXPA02006962A (en) 2000-01-17 2002-12-13 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins.
NO20002828D0 (en) * 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
JP5511117B2 (en) * 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vaccine for broad protection against diseases caused by Neisseria meningitidis
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
AU2003239666A1 (en) * 2002-05-14 2003-11-11 Affitech As Antibody screening libraries
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
ES2537737T3 (en) 2002-08-02 2015-06-11 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising lipooligosaccharides of immunotype L2 and / or L3 of Neisseria meningitidis of IgtB
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) * 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1725256A4 (en) * 2004-02-18 2008-12-31 Univ Newcastle Res Ass A vaccine formulated for administration to mucosa of the lungs
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2590974C (en) 2005-01-27 2017-10-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
SI1896065T2 (en) 2005-06-27 2014-12-31 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
US20090269362A1 (en) * 2005-07-25 2009-10-29 Sant Andrea J Method for Controlling Immunodominance
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2173759A4 (en) 2007-07-03 2014-01-29 Childrens Hosp & Res Ct Oak Oligosialic acid derivatives, methods of manufacture, and immunological uses
AU2008272854B2 (en) * 2007-07-03 2014-03-13 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
US8097591B2 (en) * 2007-07-03 2012-01-17 Children's Hospital & Research Center Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
CA2695467A1 (en) * 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US20100285069A1 (en) 2007-10-19 2010-11-11 Mario Contorni Meningococcal vaccine formulations
EP2245048B1 (en) 2008-02-21 2014-12-31 Novartis AG Meningococcal fhbp polypeptides
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
EP2326662B1 (en) * 2008-08-28 2016-11-23 The University Of Queensland Mutant bacterial glycoproteins and uses thereof
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0816284D0 (en) * 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
CN102596240B (en) 2009-08-27 2015-02-04 诺华股份有限公司 Hybrid polypeptides including meningococcal fHBP sequences
BR112012004276A2 (en) 2009-08-27 2017-10-24 Novartis Ag adjuvant comprising aluminum, oligonucleotide and polycation
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
DK2459216T3 (en) 2009-09-02 2013-12-09 Novartis Ag IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
MX2012004850A (en) 2009-10-27 2012-05-22 Novartis Ag Modified meningococcal fhbp polypeptides.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (en) 2009-12-15 2015-11-17 ノバルティス アーゲー Homogeneous suspension of immune enhancing compounds and uses thereof
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
EA023725B1 (en) 2010-03-23 2016-07-29 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
CN104114706A (en) 2012-02-02 2014-10-22 诺华股份有限公司 Promoters for increased protein expression in meningococcus
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
BR112014031386A2 (en) 2012-06-14 2017-08-01 Pasteur Institut serogroup x meningococcal vaccines
CN104602705A (en) 2012-09-06 2015-05-06 诺华股份有限公司 Combination vaccines with serogroup b meningococcus and D/T/P
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
CN105163724A (en) 2013-02-07 2015-12-16 葛兰素史密丝克莱恩生物有限公司 Pharmaceutical compositions comprising vesicles
MX2016011176A (en) 2014-02-28 2017-02-23 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides.
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3678693A1 (en) * 2017-09-08 2020-07-15 Evelo Biosciences, Inc. Bacterial extracellular vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
JPH01125328A (en) 1987-07-30 1989-05-17 Centro Natl De Biopreparados Meningococcus vaccine
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
NL9201716A (en) * 1992-10-02 1994-05-02 Nederlanden Staat Outer membrane vesicle comprising a group of polypeptides which have at least the immune function of membrane bound outer membrane proteins (OMPs), method of preparation thereof and a vaccine comprising such an outer membrane vesicle.
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
FR2751000B1 (en) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med SPECIFIC DNA FROM NEISSERIA MENINGITIDIS BACTERIA, PROCESSES FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
DE69841807D1 (en) 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic NEISSERIAL ANTIGENE
DK1047784T4 (en) 1998-01-14 2015-06-15 Novartis Vaccines & Diagnostic NEISSERA meningitidis ANTIGENS
EP2261351A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
NZ508771A (en) 1998-05-29 2003-08-29 Chiron Corp Neisseria meningitidis vaccine comprising NmC oligosaccharides, NmB outer membrane proteins, and a carrier
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
DK1185691T3 (en) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomic neonatal sequences and methods for their use
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MXPA02006962A (en) 2000-01-17 2002-12-13 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins.
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
JP5511117B2 (en) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vaccine for broad protection against diseases caused by Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2452836C (en) 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1374892A1 (en) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
ES2537737T3 (en) 2002-08-02 2015-06-11 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising lipooligosaccharides of immunotype L2 and / or L3 of Neisseria meningitidis of IgtB
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
BRPI0315228A8 (en) 2002-10-11 2018-04-03 Chiron Srl Polypeptide vaccines for broad protection against hypervirulent meningococcal strains
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2590974C (en) 2005-01-27 2017-10-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
CA2695467A1 (en) 2007-08-02 2009-03-26 Children's Hospital & Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Also Published As

Publication number Publication date
CA2416137A1 (en) 2002-02-07
US20060029621A1 (en) 2006-02-09
WO2002009643A2 (en) 2002-02-07
KR20030024811A (en) 2003-03-26
BR0112928A (en) 2003-08-26
BRPI0112928B1 (en) 2017-08-29
JP2004512269A (en) 2004-04-22
US8980285B2 (en) 2015-03-17
EP1322328B1 (en) 2014-08-20
BRPI0112928B8 (en) 2021-05-25
EP1322328A4 (en) 2005-07-20
WO2002009643A3 (en) 2002-05-30
ECSP034447A (en) 2003-04-25
CR6880A (en) 2006-08-09
MXPA03000822A (en) 2004-11-01
US20020110569A1 (en) 2002-08-15
EP1322328A2 (en) 2003-07-02
JP5511117B2 (en) 2014-06-04
US6936261B2 (en) 2005-08-30
ES2519440T3 (en) 2014-11-07
CA2416137C (en) 2013-01-29

Similar Documents

Publication Publication Date Title
AU2001280883A1 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
HK1107526A1 (en) Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2002353378A1 (en) Vaccine for periodontal disease
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2002348175A1 (en) Improved dept collection practices
AU2002309156A1 (en) Methods for dental restoration
EP1437454B8 (en) Height-adjustable edge protector
AU2001258279A1 (en) Adjuvant for vaccines
AU2002353417A1 (en) Adjuvanted antigenic meningococcal compositions
AU2003270779A1 (en) Vaccine compositions and adjuvant
EP1583506A3 (en) Eye-drop vaccine containing copolymer 1 for therapeutic immunization
AU2000279614A1 (en) Remedies for endothelin-induced diseases
AU2003245965A1 (en) Salmeterol superfine formulation
AU2003229199A1 (en) Liposome vaccine formulations for fin-fish
AU2001258550A1 (en) Insulin formulation for inhalation
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU2003264724A1 (en) Flagellin peptides as adjuvants for vaccines
AU4445201A (en) Method for administering insulin to the buccal region
AU2002335061A1 (en) Hookworm vaccine
AU2003900767A0 (en) Idiotypic vaccine
GB0308691D0 (en) Vaccine preparations
AU2001228863A1 (en) Remedies for ophthalmic diseases
AU2003244092A1 (en) 1ss-METHYLCARBAPENEM DERIVATIVE FOR ORAL ADMINISTRATION
AU2003235185A1 (en) Vaccine composition for preventing meningococcal disease
AU2001266534A1 (en) Papillomavirus vaccine